Johnson & Johnson reports network meta-analysis results showing CAPLYTA (lumateperone) favored across efficacy outcomes with no significant weight gain in adjunctive MDD treatment.
Written By: Dr. Preethi Putti, PharmD
Reviewed By: Pharmacally Editorial Team
Johnson & Johnson has reported findings from a network meta-analysis (NMA) evaluating CAPLYTA (lumateperone) as an adjunctive treatment for adults with major depressive disorder (MDD), offering indirect comparative insights in the absence of head-to-head clinical trials.
The analysis compared CAPLYTA® with other FDA-approved atypical antipsychotics used as add-on therapies to antidepressants, drawing on data from 10 randomized, placebo-controlled clinical trials. Efficacy was assessed across four endpoints: change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) score, MADRS response, MADRS remission, and change in Clinical Global Impression-Severity (CGI-S) score, alongside safety outcomes including weight change, clinically meaningful weight gain, akathisia, and somnolence.
CAPLYTA® was favored across all four efficacy outcomes and demonstrated the largest effect sizes among the evaluated treatments, including MADRS change from baseline (mean difference [MD] -4.71; 95% credible interval [CrI] -5.78, -3.63), MADRS response (odds ratio [OR] 2.33; 95% CrI 1.77, 3.05), MADRS remission (OR 2.22; 95% CrI 1.57, 3.07), and CGI-S change (MD -0.60; 95% CrI -0.74, -0.46).
In safety analyses, CAPLYTA® showed no statistically significant weight gain versus placebo plus antidepressant therapy, with favorable outcomes for mean weight change (MD -0.08; 95% CrI -0.30, 0.13) and ≥7% weight gain risk (OR 0.41; 95% CrI 0.04, 1.42).
It was the only treatment with akathisia risk comparable to placebo (OR 3.78; 95% CrI 0.40, 17.17), while somnolence risk was higher across all treatments, including CAPLYTA® (OR 5.90; 95% CrI 2.86, 11.50).
The findings were presented at the Neuroscience Education Institute Spring Congress 2026. Andrew J. Cutler, MD, lead author of the analysis, said the results provide useful indirect comparative insights where head-to-head trials are lacking and suggest adjunctive lumateperone may support meaningful symptom improvement toward remission.
Leonardo Diaz, MD, Vice President, U.S. Medical Affairs for CAPLYTA® at Johnson & Johnson, noted that differences in efficacy and tolerability across adjunctive therapies may help guide treatment decisions in patients with inadequate response to antidepressants.
Network meta-analyses are widely used to compare treatments when direct trials are unavailable, though findings rely on indirect comparisons across studies with varying designs.
Major depressive disorder affects an estimated 332 million people globally, with only about one-third of patients achieving remission on initial antidepressant therapy. CAPLYTA is an oral atypical antipsychotic approved as adjunctive therapy for MDD, as well as for schizophrenia and bipolar depression, and continues to be studied in additional neuropsychiatric indications.
Recent clinical and regulatory updates further support CAPLYTA (lumateperone), with Phase 3 data showing nearly doubled remission rates in MDD and sustained benefits for six months, alongside Johnson & Johnson securing FDA approvals for its use in both MDD and schizophrenia.
About the Writer
Dr.Preethi Putti, PharmD is a pharmaceutical researcher with experience in healthcare and pharmaceutical market research and competitive intelligence. She specializes in analyzing drug pipelines, clinical data, and industry trends and translating complex scientific data into clear and structured medical content. Strong foundation in clinical research, data interpretation, and evidence-based healthcare analysis. Committed to advancing a global career in clinical research and healthcare innovation.